Inclusion Criteria:

To receive denileukin diftitox (ONTAK) under this protocol, the patient's physician must
request this therapy for the specific patient. Patients may continue treatment with
denileukin diftitox if they:

- Are currently on therapy with denileukin diftitox and require ongoing therapy to
maintain control of their disease.

- Are willing and able to comply with all aspects of the Access Protocol

- Provide written informed consent to participate

Exclusion Criteria:

Patients are not eligible for the Access Program with denileukin diftitox if they:

• Are not currently on denileukin diftitox therapy